Neoleukin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Neurogene

20/03/2023 21:01

* Neoleukin Therapeutics Inc  NLTX.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 19 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Neoleukin Therapeutics Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 11.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Neoleukin Therapeutics Inc shares had risen by 27.4% this
quarter.
    * The company reported a quarterly loss of $13.45 million.
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $2.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 20 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.19          -0.24          Missed
 Sep. 30 2022      -0.30          -0.24          Beat
 Jun. 30 2022      -0.30          -0.28          Beat
 Mar. 31 2022      -0.30          -0.28          Beat